(Alliance News) - GlaxoSmithKline PLC on Wednesday said the European Commission has approved Nucala for use in three additional eosinophil-driven diseases.
Nucula, also known as mepolizumab, is a monoclonal antibody that targets interleukin-5, which is responsible for the maturation and release of eosinophils in the bone marrow.
The drug maker said this approval authorises mepolizumab for use as an add on treatment in hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis and chronic rhinosinusitis with nasal polyps.
Also on Wednesday, Brentford, England-based GSK and Vir Biotechnology Inc said they have secured US government contracts totalling USD1 billion to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of Covid-19. GSK will supply these doses to the US government by December 17.
In addition to the doses that will be supplied this year, the US government will have the option to purchase additional doses through March 2022.
FTSE 100-listed GSK shares were trading 0.4% lower in London on Wednesday morning at 1,551.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.